Codexis and Bristol-Myers Squibb extend the term of research agreement

Codexis Achieves Milestone

06-Feb-2006

Codexis, Inc. announced it has extended the term of an existing research agreement with Bristol-Myers Squibb Company. Codexis also announced that it will receive an undisclosed milestone payment for having successfully achieved the program's research milestone.

The research agreement was announced May 2005 and focused on improving biocatalyst productivity for an undisclosed product candidate in the Bristol-Myers Squibb pipeline using Codexis' proprietary MolecularBreeding(TM) directed evolution platform. Under the extended term of the agreement Codexis will receive additional undisclosed research funding and an additional payment, at Bristol-Myers Squibb's option, upon delivery of an enzyme for pilot-scale testing at Bristol-Myers Squibb. Further terms were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances